8-K: Celularity Inc. Announces 1-for-10 Reverse Stock Split Following Shareholder Approval

Celularity Inc. has approved a 1-for-10 reverse stock split of its Class A common stock, effective February 28, 2024, to increase the per-share trading price.

Summary

• Celularity Inc. held a special meeting on February 22, 2024, where shareholders approved a reverse stock split of the company's Class A common stock.
• The board of directors determined the ratio to be 1-for-10, meaning every ten shares of existing stock will be combined into one new share.
• The reverse stock split will be effective at 5:00 p.m. Eastern Time on February 28, 2024.
• Following the split, the company expects to have approximately 21,782,861 shares of common stock outstanding.
• No fractional shares will be issued; instead, shareholders will receive a cash payment based on the closing trading price on February 28, 2024.
• The par value per share and the number of authorized shares will remain unchanged.

Sentiment

Score: 5

Explanation: The document primarily details a reverse stock split, which is a neutral event. While it addresses a low share price, it doesn't indicate a positive or negative outlook for the company's future performance. The failure to approve the Tranche 2 warrant issuance is a slight negative.

Positives

• The reverse stock split was approved by shareholders, indicating support for the company's strategy.
• The company will provide cash payments for fractional shares, ensuring fair treatment for all shareholders.

Negatives

• A reverse stock split is often seen as a sign of a struggling stock price, which may negatively impact investor sentiment.

Risks

• The reverse stock split may not achieve the desired increase in share price and could lead to further volatility.
• The failure to approve the issuance of shares related to the Tranche 2 Warrants could impact future financing options.

Future Outlook

The company expects the reverse stock split to increase the per-share trading price of its common stock. The company will continue to operate as normal after the split.

Management Comments

• The Board approved the combination of Celularity's outstanding shares of Common Stock at a ratio of 1 for 10.
• The reverse stock split will be effective at 5:00 p.m. (Eastern Time) on February 28, 2024.

Industry Context

Reverse stock splits are often used by companies to regain compliance with stock exchange listing requirements or to make their stock more attractive to institutional investors. This action is not uncommon in the biotech industry.

Comparison to Industry Standards

• Reverse stock splits are a common strategy for companies with low share prices, particularly in the biotech sector where companies often face challenges in maintaining listing compliance.
• Other companies that have recently undertaken reverse stock splits include Cassava Sciences (SAVA) and Ocugen (OCGN), both of which are also in the biotech industry.
• The 1-for-10 ratio is within the typical range for reverse stock splits, which can range from 1-for-2 to 1-for-100.

Corporate Governance

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but the value of their holdings should remain relatively constant immediately after the split.
• Shareholders will receive cash payments for any fractional shares resulting from the split.

Next Steps

• The reverse stock split will be implemented on February 28, 2024.
• Shareholders will receive cash payments for fractional shares.

Key Dates

Keywords

reverse stock split, common stock, shareholder approval, stock split, Celularity Inc., corporate action, stock market